| Modulation of BCL-2 in both T cells and tumor cells to enhance chimeric antigen receptor T-cell immunotherapy against cancer YG Lee, P Guruprasad, G Ghilardi, R Pajarillo, CT Sauter, R Patel, ... Cancer discovery 12 (10), 2372-2391, 2022 | 55 | 2022 |
| The current landscape of single-cell transcriptomics for cancer immunotherapy P Guruprasad, YG Lee, KH Kim, M Ruella Journal of Experimental Medicine 218 (1), e20201574, 2020 | 54 | 2020 |
| Integrated automated particle tracking microfluidic enables high‐throughput cell deformability cytometry for red cell disorders P Guruprasad, RG Mannino, C Caruso, H Zhang, CD Josephson, ... American journal of hematology 94 (2), 189-199, 2019 | 31 | 2019 |
| Safety and efficacy of a novel anti-CD19 chimeric antigen receptor T cell product targeting a membrane-proximal domain of CD19 with fast on-and off-rates against non-Hodgkin … Y Zhang, RP Patel, KH Kim, H Cho, JC Jo, SH Jeong, SY Oh, YS Choi, ... Molecular cancer 22 (1), 200, 2023 | 14 | 2023 |
| Modulation of BCL-2 in both T cells and tumor cells to enhance chimeric antigen receptor T-cell immunotherapy against cancer. Cancer Discov 2022; 12: 2372–91. doi: 10.1158/2159 … YG Lee, P Guruprasad, G Ghilardi, R Pajarillo, CT Sauter, R Patel, ... CD-21-1026, 0 | 13 | |
| Apoptosis: A Janus bifrons in T-cell immunotherapy YG Lee, N Yang, I Chun, P Porazzi, A Carturan, L Paruzzo, CT Sauter, ... Journal for Immunotherapy of Cancer 11 (4), 2023 | 11 | 2023 |
| CD5 deletion enhances the antitumor activity of adoptive T cell therapies RP Patel, G Ghilardi, Y Zhang, YH Chiang, W Xie, P Guruprasad, KH Kim, ... Science Immunology 9 (97), eadn6509, 2024 | 8 | 2024 |
| The BTLA–HVEM axis restricts CAR T cell efficacy in cancer P Guruprasad, A Carturan, Y Zhang, JH Cho, KG Kumashie, RP Patel, ... Nature Immunology 25 (6), 1020-1032, 2024 | 5 | 2024 |
| Inhibition of EZH2 Improves CART19 Immunotherapy By Reprogramming Lymphoma Tumor Cells and Enhancing T-Cell Functionality P Porazzi, Y Isshiki, G Ghilardi, S Nason, Z Yang, A Carturan, L Chen, ... Blood 142, 1018, 2023 | 1 | 2023 |
| Modulation of the Btla-HVEM Axis to Enhance CAR T Cell Immunotherapy Against Cancer P Guruprasad, A Carturan, Y Zhang, KG Kumashie, IJ Cohen, G Ghilardi, ... Blood 142 (Supplement 1), 768-768, 2023 | 1 | 2023 |
| Overcoming CD19-Negative Relapses in Patients with B-Cell Lymphomas Treated with Tisagenlecleucel G Ghilardi, YG Lee, P Porazzi, I Cohen, L Paruzzo, OH Ugwuanyi, ... Blood 140 (Supplement 1), 7371-7373, 2022 | 1 | 2022 |
| Integrated Microfluidic Automated Particle Tracking Enables High-Throughput Cell Deformability Cytometry for Red Cell Disorders C Caruso, P Guruprasad, RG Mannino, H Zhang, CD Josephson, ... Blood 132, 1033, 2018 | 1 | 2018 |
| ANTI-CD30 ANTIBODY AND CHIMERIC ANTIGEN RECEPTOR COMPRISING THEREOF J Lee, J Kim, KH Kim, H Lee, M Ruella, P Guruprasad US Patent App. 18/198,937, 2024 | | 2024 |
| Overcoming the Lack of CD2: CD58 Costimulation in Chimeric Antigen Receptor T-Cell Immunotherapies A Carturan, MG Angelos, R Pajarillo, J Rodriguez, J Harris, Y Zhang, ... Blood 144, 504, 2024 | | 2024 |
| Ketogenic Diet Enhances CAR T Cell Antitumor Function Via β-Hydroxybutyrate S Liu, P Guruprasad, K Han, L Paruzzo, A Shestov, A Kelly, KR Amses, ... Blood 144, 4, 2024 | | 2024 |
| EZH1/2 Inhibition Improves the Anti-Tumor Efficacy of CAR and TCR T-Cell Based Therapies Against Multiple Liquid and Solid Tumors S Nason, Z Yang, G Ghilardi, L Paruzzo, A Carturan, E Fardella, ... Blood 144, 4792, 2024 | | 2024 |
| Streamlined measurement of chimeric antigen receptor T-cell concentration, size, viability and two-color phenotyping during manufacturing R Pajarillo, L Paruzzo, A Carturan, O Ugwuanyi, G White, P Guruprasad, ... Cytotherapy 26 (5), 506-511, 2024 | | 2024 |
| THE BTLA-HVEM AXIS RESTRAINS CHIMERIC ANTIGEN RECEPTOR T CELLS AGAINST CANCER P Guruprasad University of Pennsylvania, 2024 | | 2024 |
| Disinhibition of T Cell Activation Via CD5 Knockout Is a Universal Strategy to Enhance Adoptive T Cell Immunotherapies RP Patel, G Ghilardi, Y Zhang, P Guruprasad, MG Angelos, R Pajarillo, ... Blood 142, 102, 2023 | | 2023 |
| A First-in-Human Phase I Study of AT101, a Novel Anti-CD19 Chimeric Antigen Receptor T Cell Product Targeting a Membrane-Proximal Domain of CD19 in Adults with Relapsed or … Y Zhang, RP Patel, KH Kim, H Cho, JC Cho, SH Jeong, SY Oh, YS Choi, ... Blood 142 (Supplement 1), 2096-2096, 2023 | | 2023 |
Marco Ruella, MDUniversity of Pennsylvania在 upenn.edu 的电子邮件经过验证
